HOME >> MEDICINE >> NEWS
Updated data compares DOXIL (R)/CAELYX (TM) (doxorubicin HCl liposome injection) to Topotecan

Bridgewater, NJ, November 4, 2003 Researchers have presented updated data comparing DOXIL/CAELYX (doxorubicin HCl liposome injection) to topotecan HCl in patients with recurrent ovarian cancer. These data, from a randomized, controlled, multi-center, open-label, Phase III clinical study, were presented during a poster session at the 12th meeting of the Federation of European Cancer Societies (ECCO 12) in Copenhagen, Denmark.1

The National Cancer Institute estimates that in 2003, 25,000 American women will be diagnosed with ovarian cancer, and 14,000 women will die from it.2 This analysis compared DOXIL and topotecan another common treatment for recurrent ovarian cancer in epithelial ovarian cancer patients whose disease recurred after or did not respond to first-line, platinum-based chemotherapy. The primary objective of this long-term follow up analysis was to measure the overall survival and progression-free survival of these patients.

Researchers reported the median overall survival was three weeks longer for patients treated with DOXIL compared to those treated with topotecan (63 and 60 weeks, respectively, HR 0.82 [95 percent CI = 0.68 to 1.00]; p = 0.05). In addition, the overall progression-free survival was 16.1 weeks for DOXIL compared to 17.0 weeks topotecan (HR 0.88 [95 percent CI = 0.73 to 1.06]; p = 0.171).

Among platinum-sensitive patients (those who had a PFS interval of greater than six months after first-line, platinum-based chemotherapy), the median survival of patients receiving DOXIL was 112 weeks versus 77 weeks for patients receiving topotecan (HR 0.63 [95 percent CI = 0.47 to 0.85]; p = 0.002). DOXIL patients also saw a significant advantage in median PFS versus those receiving topotecan (28.9 and 23.1 weeks, respectively, HR = 0.76 [95 percent CI = 0.58 to 1.00]; p = 0.046).

In the subset of patients with platinum-refractory disease (those whose disease progressed during in
'"/>


4-Nov-2003


Page: 1 2 3

Related medicine news :

1. Updated adjuvant data presented at SABCS show 30 percent reduction in recurrence
2. Updated press release to October 2004 Cochrane Review
3. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
4. Updated Results On Heart Assist Device Presented At International Transplant Meeting
5. Multi-center trial compares three medications in patients with heart failure
6. Study compares overnight dialysis to treatment in centers
7. Study compares clinical diagnoses and autopsy diagnoses in ICU deaths
8. New Commonwealth Fund analysis compares candidtes health care reform proposals
9. Study compares three weekly regimens of chemotherapy for lung cancer
10. Lung cancer screening trial compares CT and standard x-ray
11. Study compares efficacy and adherence to triple nucleoside therapy Ziagen + Combivir with protease inhibitor plus Combivir regimens in therapy-nave

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 02, 2020 , ... Temprian, a spinoff from Northwestern ... Its lead indication is vitiligo. Vitiligo patients develop progressive depigmentation of the skin. ... vitiligo is equally prevalent in all ethnic groups, it is most visible and ...
(Date:7/2/2020)... ... July 02, 2020 , ... Columbia Southern University (CSU), a ... Award to Eric Simmons of Temecula, California. , CSU’s occupational safety and ... a master’s degree in occupational safety and health from the university, is the ...
(Date:7/2/2020)... ... 02, 2020 , ... The Coronavirus (COVID-19) pandemic resulted in ... conjunction with the American Dental Association and Centers for Disease Control and Prevention, ... Due to safety concerns, the announcement sparked hesitancy among some hygienists, who protested ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... botanically-derived terpenes, has officially released its new terpene infused product line including ... for consumers to enjoy cannabis terpene profiles and flavors worldwide. , “We’ve made ...
(Date:7/1/2020)... ... July 01, 2020 , ... The Society to ... of Medicine at the University of Massachusetts Medical School- Baystate and Ann Gaffey, ... the SIDM Board of Directors. Dr. Salvador and Ms. Gaffey’s service began in ...
Breaking Medicine News(10 mins):
(Date:7/10/2020)... ... July 10, 2020 , ... ... and technology for the pharmaceutical industry throughout North America has launched a ... quality pharmaceutical products. QC Corner will feature content from industry ...
(Date:7/7/2020)... ... 07, 2020 , ... To support those on the front-lines of the Covid-19 ... providing meals to the employees of Southern Nevada Health District. WGC Las Vegas will ... Wednesday, July 8th. , When asked why the Women of Global Change felt it ...
(Date:7/7/2020)... HALIFAX, Nova Scotia (PRWEB) , ... July 07, ... ... 2020 rebrand. Established in 2017, the company began as a hair service provider. ... for both in-office and work-from-home employees. Bright’s expanded offering includes beauty amenities as ...
Breaking Medicine Technology:
Cached News: